Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 254 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cardiac Event Clear all
Suspended Not applicable Interventional

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

NCT01305148
View directory record Official record
Conditions
Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions
Warfarin GenoSTAT Test
Device
Lead sponsor
Iverson Genetic Diagnostics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Jul 21, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

NCT02344290
View directory record Official record
Conditions
HIV, Cardiovascular Diseases
Interventions
Pitavastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years to 75 Years
Enrollment
7,769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
91
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 21, 2026, 11:21 AM EDT
Completed No phase listed Observational

Down Syndrome Autonomic Nervous System Induction Bradycardia

NCT05120531
View directory record Official record
Conditions
Down Syndrome, Bradycardia
Interventions
Monitoring patients undergoing surgery to look for association between ANS activity and bradycardia
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 8 Years
Enrollment
195 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Jul 21, 2026, 11:21 AM EDT
Completed Phase 3 Interventional

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

NCT01516541
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions
Background care, Placebo, dalcetrapib
Other · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
45 Years and older
Enrollment
2,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
121
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anaheim, California + 112 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 21, 2026, 11:21 AM EDT
Recruiting Not applicable Interventional

Removing Surrogates Uncertainty to Reduce Fear and Anxiety After Cardiac Events - Kids

NCT07707037
View directory record Official record
Conditions
Cardiac Arrest, Anxiety Depression, Family Support
Interventions
Education Intervention
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Days to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 21, 2026, 11:21 AM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 21, 2026, 11:21 AM EDT
Completed Not applicable Interventional Results available

Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)

NCT00933400
View directory record Official record
Conditions
Chest Pain, Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease
Interventions
CT Coronary Angiography (CTCA), Traditional Strategy
Diagnostic Test · Procedure
Lead sponsor
American College of Radiology
Other
Eligibility
30 Years and older
Enrollment
1,392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Winston-Salem, North Carolina • Hershey, Pennsylvania • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jul 21, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

Aggressive Cholesterol Therapy to Inhibit Vein Graft Events After CABG (ACTIVE Trial)

NCT01528709
View directory record Official record
Conditions
Saphenous Vein Graft Disease
Interventions
Atorvastatin 80 mg daily, Atorvastatin 10 mg daily
Drug
Lead sponsor
Boca Raton Regional Hospital
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Jul 21, 2026, 11:21 AM EDT
Completed No phase listed Observational Results available

Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events

NCT04882449
View directory record Official record
Conditions
Heart Failure
Interventions
Bodyport Cardiac Scale
Device
Lead sponsor
Bodyport Inc.
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Boynton Beach, Florida • Panama City, Florida • Gainesville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 21, 2026, 11:21 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Aspirin in Reducing Events in the Elderly-Extension (ASPREE-XT)

NCT07224347
View directory record Official record
Conditions
Functional Disability, Dementia, Heart Disease, Stroke, Cancer, Bleeding, Depression, Frailty
Interventions
Not listed
Lead sponsor
Anne Murray
Other
Eligibility
65 Years and older
Enrollment
19,114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jul 21, 2026, 11:21 AM EDT
Terminated Phase 3 Interventional

Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

NCT00580216
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Idrabiotaparinux sodium, Warfarin, Placebo (for idrabiotaparinux), Placebo (for warfarin), Avidin, Placebo (for avidin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
162
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 134 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Jul 21, 2026, 11:21 AM EDT
Not yet recruiting Phase 2 Interventional

The CARDIOPROTECT Trial

NCT07654426
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions
Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 21, 2026, 11:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Eliminate Risk of Cardiac Surgical Site Events

NCT01425697
View directory record Official record
Conditions
Surgical Site Infections
Interventions
2% Chlorhexidine Gluconate cloths, Standard of Care preoperative preparation.
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
4
States / cities
Lexington, Kentucky • Ridgewood, New Jersey • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Jul 21, 2026, 11:21 AM EDT
Completed Phase 3 Interventional Results available

Imaging of Coronary Plaques in Participants Treated With Evolocumab

NCT03570697
View directory record Official record
Conditions
Coronary Artery Disease (CAD)
Interventions
Evolocumab, Placebo, Statin therapy
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Elkhart, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Jul 21, 2026, 11:21 AM EDT
Withdrawn Not applicable Interventional

Comparison of External Event Recorders for Atrial Fibrillation Monitoring

NCT00863382
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Standard Event Monitor, Sleuth Monitor
Device
Lead sponsor
Dhanunjaya Lakkireddy, MD, FACC
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 6, 2012 · Synced Jul 21, 2026, 11:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PREVENT - Prospective Rhythm Event Surveillance in the ER With NetGuard

NCT00750958
View directory record Official record
Conditions
Cardiac Event
Interventions
NetGuard Automated Clinician Alert System
Procedure
Lead sponsor
Datascope Patient Monitoring
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2008 · Synced Jul 21, 2026, 11:21 AM EDT
Terminated Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

NCT01601704
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB32, PBO, Weight Management Program
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
8,910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
224
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Jul 21, 2026, 11:21 AM EDT
Completed Not applicable Interventional Results available

Early Case Management on Recovery From a Cardiac Event in Women

NCT04693988
View directory record Official record
Conditions
Cardiac Rehabilitation
Interventions
Case Management
Behavioral
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 21, 2026, 11:21 AM EDT
Completed Not applicable Interventional

Effects of 9-18 Weeks of Intensive Cardiac Rehabilitation After a Major Cardiovascular Event in Patients With CVD

NCT05708313
View directory record Official record
Conditions
Cardiovascular Diseases, Lifestyle Risk Reduction
Interventions
lifestyle modification
Behavioral
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
65 Years to 85 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Jul 21, 2026, 11:21 AM EDT
Completed Not applicable Interventional

Echo-guided Hemodynamic Management Strategy in Elderly Patients Undergoing Noncardiac Surgery

NCT01780727
View directory record Official record
Conditions
Ventricular Dysfunction, Left, Major Adverse Cardiac Events
Interventions
EGHEM
Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
70 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jul 21, 2026, 11:21 AM EDT
Completed No phase listed Observational

Cardiac Vulnerability in Potentially Susceptible Patients

NCT00012493
View directory record Official record
Conditions
Heart Disease
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
45 Years to 74 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2006 · Synced Jul 21, 2026, 11:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aspirin Responsiveness in Women at Risk for Cardiac Events

NCT00818337
View directory record Official record
Conditions
Heart Disease
Interventions
Aspirin
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Jul 21, 2026, 11:21 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

NCT03521934
View directory record Official record
Conditions
Heart Failure, Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
94
States / cities
Alexander City, Alabama • Cottonwood, Arizona • Little Rock, Arkansas + 83 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Jul 21, 2026, 11:21 AM EDT
Withdrawn Not applicable Interventional

Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients

NCT01305395
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Sirolimus
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Jul 21, 2026, 11:21 AM EDT